A Phase 1 interventional study of Mirikizumab - IV and Mirikizumab - SC in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 20 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-08.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to explore the safety and tolerability of mirikizumab in healthy Japanese and Caucasian participants. The study will also estimate how much mirikizumab gets into the blood stream and how long it takes the body to remove it. The study is expected to last about 16 weeks for each participant.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 200mg Mirikizumab by intravenously.
Drug: Mirikizumab - IV
Participants received single dose of either 60mgor 200mg 0r 600mg or 1200mg or 2400mg Mirikizumab by subcutaneously.
Drug: Mirikizumab - SC
Participants received placebo by intravenously.
Drug: Placebo - IV
Participants received placebo by subcutaneously.
Drug: Placebo - SC
Administered IV
Also known as: LY3074828
Administered SC
Also known as: LY3074828
Administered IV
Administered SC
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
SAE is any adverse event (AE) from this study that results in one of the following outcomes: 1. death 2. initial or prolonged inpatient hospitalization 3. a life-threatening experience (that is, immediate risk of dying) 4. persistent or significant disability/incapacity 5. congenital anomaly/birth defect 6. considered significant by the investigator for any other reason
Time frame: Baseline through Day 85
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab.
Time frame: Day 1: 0 (pre dose), end of infusion, 2, 6, 24, 72, 168, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hr post dose for IV administration; Day 1: 0 (pre dose), 6, 24, 72, 168, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hr post dose for SC administration
Pharmacokinetics: Area Under the Concentration (AUC) Curve From Time Zero to Infinity of Mirikizumab
Pharmacokinetics: Area Under the Concentration (AUC) Curve from Time Zero to Infinity of Mirikizumab.
Time frame: Day 1: 0 (pre dose), end of infusion, 2, 6, 24, 72, 168, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hr post dose for IV administration; Day 1: 0 (pre dose), 6, 24, 72, 168, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hr post dose for SC administration
| Milestone | Placebo Subcutaneous (SC) | Placebo IV | 60mg Mirikizumab IV | 200mg Mirikizumab SC | 200mg Mirikizumab IV | 600mg Mirikizumab IV | 1200mg Mirikizumab IV | 2400mg Mirikizumab IV |
|---|---|---|---|---|---|---|---|---|
| Started | 2 | 10 | 6 | 6 | 6 | 9 | 6 | 6 |
| Received at least one dose of study drug | 2 | 10 | 6 | 6 | 6 | 9 | 6 | 6 |
| Completed | 2 | 8 | 6 | 6 | 6 | 8 | 6 | 6 |
| Not completed | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
SAE is any adverse event (AE) from this study that results in one of the following outcomes: 1. death 2. initial or prolonged inpatient hospitalization 3. a life-threatening experience (that is, immediate risk of dying) 4. persistent or significant disability/incapacity 5. congenital anomaly/birth defect 6. considered significant by the investigator for any other reason
| Participants | Placebo SC | Placebo IV | 60mg Mirikizumab IV | 200mg Mirikizumab IV | 200mg Mirikizumab SC | 600mg Mirikizumab IV | 1200mg Mirikizumab IV | 2400mg Mirikizumab IV |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab.
| Microgram per Milliliter (μg/mL) | 60mg Mirikizumab IV | 200mg Mirikizumab SC | 200mg Mirikizumab IV | 600mg Mirikizumab IV | 1200mg Mirikizumab IV | 2400mg Mirikizumab IV |
|---|---|---|---|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab | 23.1 ± 9 | 11.8 ± 39 | 78.8 ± 13 | 250 ± 16 | 454 ± 11 | 985 ± 20 |
Pharmacokinetics: Area Under the Concentration (AUC) Curve from Time Zero to Infinity of Mirikizumab.
| Microgram day per milliliter (μg*day/mL) | 60mg Mirikizumab IV | 200mg Mirikizumab SC | 200mg Mirikizumab IV | 600mg Mirikizumab IV | 1200mg Mirikizumab IV | 2400mg Mirikizumab IV |
|---|---|---|---|---|---|---|
| Pharmacokinetics: Area Under the Concentration (AUC) Curve From Time Zero to Infinity of Mirikizumab | 148 ± 29 | 210 ± 29 | 539 ± 12 | 1970 ± 24 | 2900 ± 14 | 5990 ± 12 |
Collected over Up to 88 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo SC | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Placebo IV | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| 60mg Mirikizumab IV | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| 200mg Mirikizumab SC | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| 200mg Mirikizumab IV | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| 600mg Mirikizumab IV | 0/9 (0%) | 0/9 (0%) | 1/9 (11.1%) |
| 1200mg Mirikizumab IV | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| 2400mg Mirikizumab IV | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Event | Placebo SC | Placebo IV | 60mg Mirikizumab IV | 200mg Mirikizumab SC | 200mg Mirikizumab IV | 600mg Mirikizumab IV | 1200mg Mirikizumab IV | 2400mg Mirikizumab IV |
|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 1/2 | 1/10 | 1/6 | 0/6 | 1/6 | 0/9 | 0/6 | 0/6 |
| Post-traumatic neck syndromeInjury, poisoning and procedural complications | 1/2 | 0/10 | 0/6 | 0/6 | 0/6 | 0/9 | 0/6 | 0/6 |
| Sinus arrhythmiaCardiac disorders | 0/2 | 0/10 | 1/6 | 0/6 | 0/6 | 0/9 | 0/6 | 0/6 |
| FatigueGeneral disorders | 0/2 | 0/10 | 0/6 | 0/6 | 0/6 | 0/9 | 0/6 | 1/6 |
| RhinitisInfections and infestations | 0/2 | 0/10 | 1/6 | 0/6 | 0/6 | 0/9 | 0/6 | 0/6 |
| Urinary tract infectionInfections and infestations | 0/2 | 1/10 | 0/6 | 1/6 | 0/6 | 0/9 | 0/6 | 0/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/2 | 0/10 | 1/6 | 0/6 | 0/6 | 0/9 | 0/6 | 0/6 |
| RashSkin and subcutaneous tissue disorders | 0/2 | 0/10 | 0/6 | 0/6 | 1/6 | 0/9 | 0/6 | 0/6 |
| Infusion site extravasationGeneral disorders | 0/2 | 0/10 | 0/6 | 0/6 | 0/6 | 1/9 | 0/6 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 0/2 | 1/10 | 0/6 | 0/6 | 0/6 | 0/9 | 0/6 | 0/6 |
All randomized participants.
| Age, Continuous(years) | Placebo SC | Placebo IV | 60mg Mirikizumab IV | 200mg Mirikizumab SC | 200mg Mirikizumab IV | 600mg Mirikizumab IV | 1200mg Mirikizumab IV | 2400mg Mirikizumab IV | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 48.5 ± 2.1 | 45.7 ± 10.6 | 49.3 ± 9.4 | 37.3 ± 8.8 | 41.7 ± 16.0 | 46.8 ± 11.9 | 37.8 ± 11.9 | 45.2 ± 6.0 | 44 ± 11 |
| Sex: Female, Male(Participants) | Placebo SC | Placebo IV | 60mg Mirikizumab IV | 200mg Mirikizumab SC | 200mg Mirikizumab IV | 600mg Mirikizumab IV | 1200mg Mirikizumab IV | 2400mg Mirikizumab IV | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 6 | 3 | 3 | 5 | 5 | 3 | 5 | 31 |
| Male | 1 | 4 | 3 | 3 | 1 | 4 | 3 | 1 | 20 |
| Ethnicity (NIH/OMB)(Participants) | Placebo SC | Placebo IV | 60mg Mirikizumab IV | 200mg Mirikizumab SC | 200mg Mirikizumab IV | 600mg Mirikizumab IV | 1200mg Mirikizumab IV | 2400mg Mirikizumab IV | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 3 | 0 | 2 | 2 | 1 | 9 |
| Not Hispanic or Latino | 2 | 9 | 6 | 3 | 6 | 7 | 4 | 5 | 42 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo SC | Placebo IV | 60mg Mirikizumab IV | 200mg Mirikizumab SC | 200mg Mirikizumab IV | 600mg Mirikizumab IV | 1200mg Mirikizumab IV | 2400mg Mirikizumab IV | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 5 | 3 | 3 | 3 | 5 | 3 | 3 | 26 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 1 | 5 | 3 | 3 | 3 | 4 | 3 | 3 | 25 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo SC | Placebo IV | 60mg Mirikizumab IV | 200mg Mirikizumab SC | 200mg Mirikizumab IV | 600mg Mirikizumab IV | 1200mg Mirikizumab IV | 2400mg Mirikizumab IV | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 2 | 10 | 6 | 6 | 6 | 9 | 6 | 6 | 51 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2015 to primary completion in Jul 2018, 31 months.
Results were first posted in Feb 2024, 5 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab